- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | The Latest Analyst Ratings For Arcellx | 1 | Benzinga.com | ||
| 31.05. | Expert Ratings For Arcellx | 3 | Benzinga.com | ||
| 14.05. | Analyst Expectations For Arcellx's Future | 2 | Benzinga.com | ||
| 10.05. | Arcellx GAAP EPS of -$0.14, revenue of $39.3M | 1 | Seeking Alpha | ||
| 09.05. | Gilead's Kite, Arcellx share phase 3 trial design for CAR-T multiple myeloma asset | 18 | Seeking Alpha | ||
| 09.05. | Arcellx, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 09.05. | Arcellx Provides First Quarter 2024 Financial Results | 52 | Business Wire | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
| 23.04. | Should You Be Bullish on Arcellx (ACLX)? | 3 | Insider Monkey | ||
| 25.03. | Arcellx director sells over $35 million in company stock | 1 | Investing.com | ||
| 19.03. | Arcellx CFO sells over $470k in company stock | 1 | Investing.com | ||
| 18.03. | Arcellx director Ware sells over $630k in company stock | 1 | Investing.com | ||
| 18.03. | Needham raises Arcellx stock target to $81, maintains buy rating | - | Investing.com | ||
| 14.03. | Arcellx, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.03. | Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley | 14 | Benzinga.com | ||
| 07.03. | Morgan Stanley bullish on Arcellx shares after myeloma data 'promising' | 5 | Investing.com | ||
| 05.03. | Arcellx shares target raised by Truist on CAR-T potential | 3 | Investing.com | ||
| 29.02. | Arcellx Analysts Boost Their Forecasts After Q4 Results | 1 | Benzinga.com | ||
| 28.02. | Arcellx, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.02. | Arcellx, Inc.: Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights | 682 | PR Newswire | -- Expanded strategic partnership with Kite --
-- Presented continued robust long-term responses from Phase 1 expansion trial of anito-cel (formerly CART-ddBCMA) in patients with relapsed or refractory... ► Artikel lesen | |
| 31.01. | Arcellx, Inc. - 8-K, Current Report | 1 | SEC Filings |
Seite:
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,010 | -25,46 % | EQS-News: Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024 | EQS-News: Epigenomics AG
/ Schlagwort(e): Personalie
Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024
30.04.2024 / 15:00 CET/CEST
Für den Inhalt... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,612 | +0,66 % | EQS-News: Defence Therapeutics Inc.: Der wissenschaftliche Leiter von Defence, Dr. Moutih Rafei, spricht auf Money Talk Radio mit Ellis Martin über die Accum-Platform zur Krebsbekämpfung | EQS-News: Defence Therapeutics Inc.
/ Schlagwort(e): Sonstiges
DER WISSENSCHAFTLICHE LEITER VON DEFENCE, DR. MOUTIH RAFEI, SPRICHT AUF MONEY TALK RADIO MIT... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,392 | -0,51 % | Ginkgo Bioworks Holdings, Inc. - 8-K, Current Report | ||
| BEAM THERAPEUTICS | 23,170 | 0,00 % | Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease | MADRID, June 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported data highlighting... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 9,700 | +3,52 % | Recursion Pharmaceuticals: Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry | SALT LAKE CITY, May 13, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the completion... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,945 | 0,00 % | Oncolytics Biotech® Inc.: Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action | Trial-in-progress abstract highlights new cohort that could expand the company's pancreatic cancer program
Pelareorep's ability to expand TILs highlights its immunotherapeutic mechanism... ► Artikel lesen | |
| ASSERTIO | 1,095 | +4,29 % | Assertio Holdings And 2 Other Penny Stocks Insiders Are Buying | ||
| ARCTURUS THERAPEUTICS | 25,960 | 0,00 % | Arcturus Therapeutics Holdings Inc. - 8-K, Current Report | ||
| VIR BIOTECHNOLOGY | 8,950 | -2,51 % | Vir Biotechnology, Inc.: Multiple Abstracts Highlighting Vir Biotechnology's Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024 | - Company to present important new data from the Phase 2 SOLSTICE chronic hepatitis delta trial - - Conference call scheduled for June 5, 2024, at 6:00 a.m. ET 12:00 p.m. CEST -
Vir Biotechnology... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 6,330 | 0,00 % | SIGA Technologies Inc.: SIGA Announces Agreement to Sell TPOXX® to ASEAN Member States | ||
| MERRIMACK PHARMACEUTICALS | 15,130 | 0,00 % | Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") announced that the stockholders at a Special Meeting held today overwhelmingly approved... ► Artikel lesen | |
| VERVE THERAPEUTICS | 5,100 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, May 31, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ADMA BIOLOGICS | 10,620 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV & BIVIGAM | FDA Approval Provides for Room Temperature (25°C) Storage Conditions for up to 4 Weeks at Any Point During the 36-Month Approved Shelf Life Extends the Prior Room Temperature Storage Allowance for... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 8,100 | 0,00 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response for neffy (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand | CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat... ► Artikel lesen | |
| RELAY THERAPEUTICS | 7,030 | -0,85 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608 | CAMBRIDGE, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge... ► Artikel lesen |
ARCELLX INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 53,81 Euro und damit +0,11 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
